Investment Pitches

Pitch Summary:
Medical device manufacturer Cooper Companies is a global leader in contact lenses and women’s health and fertility care. We initiated a position as revenue growth deceleration and transitory execution challenges weighed on valuation. Long term, growth in the contact lens industry is expected to remain healthy. The company is positioned to gain modest market share. Investments in women’s health should pay off as cyclical headwinds ease.

BSD Analysis:
Cooper is a quiet medtech compounder built on vision correction and women’s health, two categories driven by demographics rather than cycles. Contact lenses behave like consumables once patients are fitted, creating recurring revenue that doesn’t show up in headline growth debates. Investors worry about competition and miss how sticky practitioner relationships really are. In women’s health, regulatory barriers protect incumbents more than they slow them. Margins expand through mix and scale, not blockbuster innovation. Execution consistency matters more than flash here. This is healthcare demand hiding inside a “boring” device company.

Pitch Summary:
Shares of food products manufacturer Sysco declined given investor concern surrounding the macro environment for restaurants and the weakening consumer. Traffic softness and spending uncertainty weighed on sentiment. Despite these concerns, the company retains a market-leading position. Sysco benefits from significant buying power, route density, and a wide product assortment. These structural advantages underpin long-term competitiveness.

BSD Analysis:
Sysco is foodservice infrastructure, not a restaurant traffic trade. When menus change, costs spike, or kitchens struggle with labor, Sysco still moves product because complexity doesn’t disappear. Scale and route density give Sysco pricing power that smaller distributors simply can’t replicate. Investors fixate on restaurant cycles and miss the non-discretionary nature of food distribution. Private-label penetration and data-driven sourcing quietly expand margins over time. Labor and fuel inflation hurt optics but are largely passed through. This is logistics math tied to eating, which turns out to be remarkably durable.

Pitch Summary:
Shares of leading diagnostic lab Labcorp declined amid investor concern surrounding lower-than-expected guidance. The weakness was driven by delays in acquisition closings and softness in its development pipeline. These factors prompted a restructuring of that business. Despite the near-term challenges, Labcorp maintains strong competitive advantages. Its scale enables low-cost operations and better-than-average margins over time.

BSD Analysis:
Labcorp is diagnostics infrastructure, not a pandemic trade — even if the market forgot that. Routine testing, drug development services, and clinical trials drive recurring demand. Volume normalized post-COVID, exposing the real earnings power underneath the noise. Scale matters because payers and pharma want fewer, reliable partners. Pricing pressure exists, but cost discipline offsets it over time. The drug development segment adds countercyclical balance. This is not a high-growth healthcare name. It’s medical plumbing with operating leverage. Labcorp compounds when execution is boring and volumes stay steady.

Pitch Summary:
Pet and livestock pharmaceutical manufacturer Zoetis underperformed in Q4 after reducing its 2026 outlook, citing fewer veterinary visits by pet owners. Investor concerns centered on near-term demand softness in the companion animal market. Despite this, management maintains a strong long-term view supported by a broad portfolio. The company has multiple growth drivers and a robust pipeline targeting undertreated conditions. Long-term fundamentals remain intact despite near-term pressure.

BSD Analysis:
Zoetis operates in animal health where demand is emotionally sticky and pricing power is real. Pet owners don’t delay treatment the way they delay electronics purchases. The portfolio spans livestock and companion animals, smoothing economic cycles. Innovation is incremental but defensible, protecting margins. Competition exists, yet switching products often risks outcomes veterinarians won’t gamble with. Growth is steady, not explosive — exactly what infrastructure looks like. Capital allocation remains disciplined. This is not a biotech lottery ticket. It’s healthcare for animals with predictable compounding.

Pitch Summary:
Consumer finance company Capital One Financial Group outperformed during the quarter following strong Q3 results, with better-than-expected revenue and expense trends. Shares also benefited from management’s clarity around accelerating share buybacks. Generally favorable economic data during the period supported investor confidence in spending and credit trends. The company’s scale in credit cards continues to drive attractive returns. These dynamics contributed positively to relative performance.

BSD Analysis:
Capital One thrives where complexity scares competitors — consumer credit, data, and digital infrastructure. Its underwriting and analytics capabilities allow it to price risk better than most peers. Credit cycles will always matter, but Capital One is structurally prepared for them. The Discover acquisition adds scale and payments leverage, but execution will be scrutinized. Net interest margins fluctuate, yet fee and interchange revenue provide balance. Capital levels are solid, giving flexibility through cycles. This is not a pristine bank. It’s a calculated risk-taker with real data advantages. Capital One works when discipline beats optimism.

Pitch Summary:
Property and casualty insurer American International Group reported better-than-expected earnings, with strong expense management and share repurchases offsetting a weakening pricing environment. Shares also benefited from reports that fellow insurer Chubb is exploring a potential acquisition of the company. Management’s focus on operational efficiency continues to improve profitability. Capital return remains a key component of the investment case. These factors combined to drive strong performance during the quarter.

BSD Analysis:
AIG is no longer the financial cautionary tale it once was — it’s a leaner insurer focused on underwriting discipline. The company shed distractions and rebuilt its balance sheet with fewer heroics and more math. Property-casualty pricing remains rational, supporting margins if risk selection holds. Volatility hasn’t disappeared, but it’s now managed rather than ignored. Capital allocation has improved, with buybacks doing real work. The market still prices AIG for past sins, not current behavior. Growth isn’t exciting, but returns don’t need to be. This is not a comeback hype story. It’s a repaired insurer quietly earning its way back into relevance.

Pitch Summary:
Automobile manufacturer General Motors saw strong results as volumes have stabilized across the auto industry. The company has also taken market share while maintaining pricing and growing in the electric vehicle and software services spaces. The stabilization of industry volumes has allowed GM to better leverage its scale and cost structure. Management continues to balance profitability with investment in EV platforms and software-driven services. These dynamics supported strong relative performance during the quarter.

BSD Analysis:
General Motors is the most misunderstood legacy automaker, trading like a melting ice cube while behaving more like a cash-generating industrial platform. The market fixates on EV losses and ignores that GM’s ICE and truck franchises still throw off enormous free cash flow. EVs are not the business today — they’re a capital allocation option funded by a very profitable core. Cruise setbacks hurt credibility, but they don’t impair the balance sheet or the manufacturing engine. Scale matters in autos, and GM has it in purchasing, platforms, and North American dominance. Investors underestimate how much pricing power remains in trucks, SUVs, and commercial fleets. The dividend and buybacks are not cosmetic; they’re funded by real cash, not leverage. GM doesn’t need EVs to work tomorrow to justify today’s valuation. This is old-world manufacturing with financial discipline, priced as if collapse is inevitable.

Pitch Summary:
SK hynix, a leading South Korean memory chip manufacturer, operates in a consolidated industry and is benefiting from increased demand for higher-value products such as high-bandwidth memory used in data centers and AI applications. The stock’s valuation still reflects that of a traditional memory cycle rather than a sustained shift toward higher-value products.

BSD Analysis:
SK hynix sits at the center of the AI hardware stack whether investors like memory cycles or not. High-bandwidth memory is no longer a commodity add-on — it’s a performance bottleneck, and hynix leads where it matters. Downcycles punish earnings optics, but they also clear weaker competitors and tighten future supply. Investors fixate on DRAM volatility and miss how differentiated hynix has become at the high end. Capital intensity is brutal, which is exactly why the moat holds. Pricing power returns fast when inventories normalize. This is semiconductor leverage to AI infrastructure, not consumer gadget beta.

Pitch Summary:
Century Aluminum sits at the intersection of AI data-center buildout and renewed defense and energy security priorities. Data centers, EVs, and clean energy are tightening domestic aluminum supply, driving higher Midwest premiums and incentivizing the restart of idled U.S. smelting capacity. Century is repositioning itself as a strategic U.S. metals asset, investing to restart Mt. Holly capacity and securing long-term power contracts to protect margins, while supplying high-purity aluminum critical for defense applications.

BSD Analysis:
Century Aluminum is a levered bet on primary aluminum supply in a world that keeps talking about electrification while starving smelters of capital. Aluminum demand is structurally supported by EVs, renewables, packaging, and lightweighting, yet Western supply remains constrained by energy costs and ESG politics. Investors fixate on commodity volatility and miss how tight capacity actually is outside China. Power contracts and energy pricing matter more than spot aluminum prices in determining upside here. When smelters shut, they don’t restart easily, which quietly increases the value of surviving assets. Balance sheet risk is real, but that leverage cuts both ways in tightening markets. This is not a steady compounder — it’s scarcity optionality tied to industrial reality. When aluminum prices move, Century doesn’t whisper.

Pitch Summary:
Caterpillar is increasingly a software- and data-driven industrial platform rather than a pure equipment manufacturer, using connected machines, cloud analytics, and AI to grow high-margin services and smooth cyclicality. The company has built a unified digital platform, Helios, connecting over 1.4 million assets and targeting $28 billion in services revenue by 2026. At CES 2026, Caterpillar showcased AI-powered tools enabling predictive maintenance, autonomous operations, and digital twins, further embedding Cat into customer workflows.

BSD Analysis:
Caterpillar thrives when infrastructure, mining, and energy investment get real — not theoretical. Its dealer network and aftermarket parts business create recurring cash flow beyond new equipment sales. Pricing power exists because downtime is more expensive than sticker shock. Cyclicality remains, but replacement demand and services cushion downturns. Electrification and autonomy add optionality without threatening the core. Capital allocation has been shareholder-friendly through cycles. This is not a China stimulus trade. It’s global heavy equipment infrastructure with embedded leverage. Caterpillar compounds by owning the dirt-moving economy.

Pitch Summary:
Eli Lilly stands out as a dominant franchise in the GLP-1 obesity and diabetes market, while actively reducing friction for patients and payers through direct-to-consumer and direct-to-employer pricing strategies that bypass pharmacy benefit manager middlemen. Through LilyDirect, cash-pay patients can now access Zep Bound at significantly discounted prices, and Lilly has struck agreements to expand access through employers and Medicare channels. Beyond metabolics, Lilly is diversifying into oncology and next-generation oral GLP-1s, including orforglipron, which offers meaningful convenience advantages and could become a mega-blockbuster.

BSD Analysis:
Eli Lilly is redefining what “growth pharma” looks like in real time. GLP-1 drugs for obesity and diabetes are reshaping healthcare economics, not just market share. Demand exceeds supply, which is the best possible problem to have. Pricing power is enormous even as political noise grows louder. The pipeline behind today’s blockbusters is credible, not speculative. Manufacturing investment is heavy but rational. Margins expand as scale catches up with demand. This is not defensive pharma anymore. It’s a structural earnings reset with momentum.

Pitch Summary:
Kodiak Gas Services is a ‘picks-and-shovels’ play on the U.S. natural gas boom. The company provides mission-critical large-horsepower compression infrastructure that sits upstream of LNG exports and downstream power demand from AI-driven data centers. In our view, Kodiak’s long-term, take-or-pay style contracts, high fleet utilization, and structurally tight compression market can translate robust demand in the Permian and other basins into steady EBITDA growth, rising discretionary cash flow, and a high-single-digit total return profile before any multiple expansion.

BSD Analysis:
Kodiak sits in the unsexy but critical business of natural gas compression, where uptime matters more than commodity prices. Long-term contracts create recurring revenue and reduce direct exposure to gas price swings. Demand is driven by growing gas production and infrastructure buildout, not speculation. Capital intensity is high, making fleet utilization and pricing discipline essential. Scale provides operating leverage when utilization tightens. This is not a drilling services lottery ticket. It’s infrastructure-like energy services with visibility. Kodiak works when management resists growth for growth’s sake.

Pitch Summary:
The overweight position to healthcare stock Fortrea Holdings Inc. (FTRE) had a positive impact on performance. FTRE ranked in the top 50% of the universe and had attractive factors embedded in the stock, which led to the overweight holding. During the quarter, the stock rose boosted by strong net bookings.

BSD Analysis:
Fortrea is CRO infrastructure carved out of a larger system and still finding its independent footing. Drug development doesn’t stop when funding tightens — it just shifts toward operators that can execute cleanly. Investors treat Fortrea like a broken spin and miss the embedded relationships and trial backlog. Margin pressure reflects transition noise more than structural weakness. Scale and regulatory credibility matter more than branding in clinical research. As operations stabilize, earnings power becomes clearer. This is life-sciences plumbing rebuilding credibility, not a melting ice cube.

Pitch Summary:
An overweight position in Amicus Therapeutics, Inc. (FOLD) contributed to performance. Amicus is a commercial stage biotechnology company focused on rare disease therapies. The stock ranked in the top 25% of the universe, driven primarily by its quality features relative to its small cap peers. During 4Q25, it delivered strong results as product sales rose both domestically and abroad.

BSD Analysis:
Amicus is a rare-disease biotech where execution now matters more than science. Galafold proved the company can commercialize in ultra-orphan markets with real pricing power. Investors fixate on cash burn and pipeline risk while ignoring how sticky rare-disease franchises become once established. Regulatory pathways and physician relationships create barriers that don’t show up in TAM slides. The pipeline adds upside, but the base business already works. Dilution risk exists, but so does leverage to operating scale. This is biotech compounding in a narrow lane, not a binary moonshot.

Pitch Summary:
A non-benchmark position in Flowserve Corp. (FLS) had a positive impact on performance. FLS is an industrials stock that manufactures pumps, valves, and flow control systems for energy, chemicals, power, and industrial infrastructure. The ML models rank it in the top 10% of the universe, driven by its valuation and volatility features. During the quarter the stock rose after delivering strong 4Q25 results.

BSD Analysis:
Flowserve sells mission-critical flow control equipment where failure is catastrophic and switching is not casual. Pumps, valves, and seals don’t sound exciting until you realize they sit inside energy, chemicals, power, and water systems that cannot go down. After years of operational cleanup, execution has tightened and margins are finally behaving. Investors still anchor to legacy industrial cyclicality and miss the aftermarket and service annuity embedded in the installed base. Energy transition capex doesn’t bypass Flowserve — it reroutes through it. Pricing power shows up quietly when uptime is non-negotiable. This is industrial infrastructure paid to be boring and correct, not fast and flashy.

Pitch Summary:
An overweight to the industrial stock GEO Group Inc. (GEO) detract from performance. The company is ranked in the top 25% of the universe, driven primarily by its valuation features. Within the valuation composite, EBITDA, operating cash flow to price, and performance of value features drove the score up. GEO fell during the quarter after reporting revenues below expectations and elevated administrative expenses tied to restructuring.

BSD Analysis:
GEO Group operates in one of the most politically toxic but economically resilient corners of real estate and services. Government contracts for correctional and detention facilities provide long-term cash flow visibility. Political rhetoric creates headline risk but hasn’t eliminated demand. Leverage is the central risk — everything else is noise. Capital allocation is focused on debt reduction rather than growth. Cash generation remains strong because alternatives are limited and expensive. This is not an ESG-friendly investment. It’s a cash-flow trade in an unpopular asset class. GEO works if debt keeps coming down faster than politics change.

Pitch Summary:
An overweight position in the real estate stock Hudson Pacific Properties, Inc. (HPP) detract from performance. The company ranks in the top 15% of the universe, driven by the ML model's favorable view of its valuation and momentum of fundamental features. HPP is a West Coast office and studio real estate investment trust (REIT) serving technology and media tenants. The stock fell during the quarter as new leasing activity fell short of expectations.

BSD Analysis:
Hudson Pacific is an office REIT caught in the crossfire of remote work and rising rates. Asset quality matters, but leasing demand remains under pressure. Studio assets add diversification, but Hollywood volatility hasn’t helped. Balance-sheet leverage amplifies both downside risk and any recovery. Cash flow visibility is weak until leasing stabilizes. This is not a defensive REIT. It’s a leveraged bet on office normalization. Upside exists if sentiment turns faster than fundamentals. Hudson Pacific is a survival-first story, not a compounding one.

Pitch Summary:
An underweight position in Bloom Energy Corp. (BE) detract from performance. The machine learning (ML) models have a highly unfavorable view of Bloom Energy, which ranked zero at the start of the quarter. The primary driver of the low score were its valuation features. During the quarter the stock rose significantly given rising demand from AI-related data center power needs.

BSD Analysis:
Bloom Energy sells power reliability wrapped in a clean-energy narrative. Its solid oxide fuel cells appeal where grid failure is unacceptable, regardless of emissions debates. Revenue growth looks attractive, but profitability remains elusive due to capital intensity and execution challenges. Policy support helps, but subsidies aren’t a business model. Customers buy Bloom for uptime, not ideology. Margins can improve if scale and cost reductions finally show up. This is not a sure thing energy transition winner. It’s a technology bet with real adoption but fragile economics. Bloom works only if engineering discipline catches up to ambition.

Pitch Summary:
Liquidia recently pre-announced very strong results and is on track for $600–700m in sales this year. The primary overhang is a patent dispute with United Therapeutics, which we believe will be resolved favorably. Even in an adverse outcome, the downside is hedged, while upside from litigation success and a potential sale is substantial.

BSD Analysis:
Liquidia is a specialty pharma company built around reformulating known drugs to compete on delivery and economics. Its inhaled treprostinil program targets a real market with entrenched incumbents. The risk isn’t science — it’s legal, regulatory, and commercial execution. Patent disputes and launch timing dominate the narrative more than clinical data. If approved and commercialized successfully, margins can scale fast due to focused distribution. Cash burn and dilution remain live risks. This is not biotech moonshot investing. It’s asymmetric litigation-plus-launch risk. Liquidia is binary, but not imaginary.

Pitch Summary:
Dave is a high-growth, profitable neobank serving 14 million members with a highly efficient digital model. Its core Extracash product has seen declining credit losses and rising profitability. The company plans to expand into BNPL, leveraging its underwriting expertise. We believe Dave can grow earnings 20%+ annually and is materially undervalued relative to fintech peers.

BSD Analysis:
Dave lives in the brutally competitive world of consumer fintech where survival is the first victory. Its core value proposition — avoiding overdraft fees — resonates because banks still punish liquidity mistakes. Unit economics have improved as marketing discipline replaced growth theatrics. Monetization is narrow, which keeps execution risk high. Scale matters because customer acquisition costs don’t forgive hesitation. Regulation is both a threat and a barrier to entry. This is not a platform business yet. It’s a scrappy operator fighting for relevance in consumer finance. Dave works only if discipline keeps beating ambition.